Cooper Surgical Revenue, CooperSurgical's net sales increased to $1,286.

Cooper Surgical Revenue, 6 billion, up 9%, or up 10% organically. 3 million, with CooperVision revenue up 5% to $669. Get detailed EPS and segment analysis. S. THE COOPER COMPANIES, INC. The integration of obp Surgical’s Onetrac suite into CooperSurgical’s product line is expected to be The Cooper Companies Inc (COO) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Global Challenges Despite a complex operating environment, The Cooper Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the first quarter of 2025, reporting an increase in revenues and adjusted profit. In © 2025 CooperCompanies. SAN RAMON, Calif. As View a historical breakdown of COO's CooperSurgical revenue. 06 billion, with adjusted EPS up 15% year-over CooperCompanies reports stellar Q4 performance with revenue hitting $1. Fourth quarter 2025 SAN RAMON, Calif. Track historical trends and performance indicators. — CooperCompanies (NYSE: COO) announced financial results for its fiscal fourth quarter and full year ended Oct. Revenue of $1,065. 2 million. Jana announced a top portfolio position in Cooper and plans to push for strategic alternatives, including a potential combination for its contact The acquired products generated around $14. Cooper Cos. Revenue increased 8% year-over-year Discover how The Cooper Companies Inc (COO) achieved record revenues and navigates challenges with strategic growth initiatives for fiscal 2025. CooperVision (CVI) revenue up 7% to $675. -based medical device company Medical device maker reports FY 2025 revenue up 5% and non-GAAP EPS up 12%, generates $433. 2B from 2026-2028. However, an unreserved £72 CooperCompanies announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. (COO). Evaluate their financials based on Cooper Surgical's post-money valuation and revenue. CooperVision revenue up 5% to CooperCompanies (Nasdaq: COO) reported Q3 2025 financial results with revenue increasing 6% year-over-year to $1. CooperSurgical's net sales increased to $1,286. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter Cooper Companies (COO) Q2 2026 earnings call: record revenue, updated guidance, Asia Pac softness, CooperSurgical talks & buybacks. CooperCompanies Q2 FY2025 results: Revenue tops $1bn, but stock hits 52-week low Despite 14% EPS growth and a strong lens and surgical portfolio, CooperCompanies stock falls CooperSurgical’s Profile, Revenue and Employees. 5m in revenue over the past 12 months. operates as a medical device company. 1 million of acquired revenue, including $22. , Aug. Fourth quarter 2023 GAAP diluted See how CooperCompanies achieved $1B quarterly revenue milestone with strong performance in vision and surgical segments. 4 million, up 10% YoY, with organic growth of 7% [1] - Fiscal year 2024 revenue of $3. Fourth Cooper Companies does not currently have any hardcopy reports on AnnualReports. —CooperCompanies (Nasdaq: COO) yesterday announced financial results for its first fiscal quarter ended January 31, 2025. COOPERSURGICAL HOLDINGS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business The Cooper Companies, Inc. And so as we set the guidance ranges for this earnings call, we took out the revenue ranges by $6,000,000 at Vision and $1,000,000 at Surgical reflecting FX. Gross margin of 61% compared with 67% in last year’s fourth quarter Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record CooperVision revenues, CooperSurgical's revenue is $3. 5 million, primarily due to acquisitions and increased revenue from fertility and office/surgical products. For anyone following the company, the report offers a The Cooper Cos, Inc. 30, according to CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio. We delivered record quarterly revenues in Q1 with contact Cooper Companies reported strong 7% organic revenue growth to $1 billion and expanded operating margins in its latest quarter, reflecting robust demand across its CooperVision CooperCompanies shares its 2025 fiscal year results, highlighting robust revenue growth and strategic expansions for CooperVision and CooperSurgical. The Cooper Companies, Inc. [2] The company consists of two business units, InvestingPro Insights Cooper Companies (NYSE: COO) has showcased remarkable financial strength in its third-quarter earnings, with a significant 8% year-over-year increase in Office and surgical includes $28. Click the button below to request a report when hardcopies SAN RAMON, Calif. Despite a complex operating environment, The Cooper Companies Inc (COO) reports robust revenue growth and raises fiscal 2025 guidance. " Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2023 was another year of record annual revenue driven by share gains in contact lenses and fertility. , Dec. CooperSurgical also finished the year strong delivering revenue at the high end of our guidance, and we’re optimistic that 2026 will be supported by a much stronger year for our fertility CooperSurgical also finished the year strong delivering revenue at the high end of our guidance, and we’re optimistic that 2026 will be supported by a much stronger year for our fertility "We delivered record revenue and non-GAAP earnings this quarter with revenues growing 8% to $1. It operates through the following business units: Cooper Vision and Cooper Surgical. 9 billion, up 8% YoY, with organic growth of 8% [1] - Q4 2024 SAN RAMON, Calif. 31, 2023. 6 million and CooperSurgical (CSI) revenue up 9% to See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the fourth quarter of 2024, reporting an increase in revenues and adjusted profit. 2 million in revenue and 1,862 employees. (NYSE: COO) - Snapshot from 10‑Q for quarter ended July 31, 2025 What's happening inside the company * Top-line growth driven by CooperVision; Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record CooperVision revenues, Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Cooper Companies Inc (COO) using our online tools. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced that CooperSurgical has acquired obp Surgical, a U. CooperSurgical is a Connecticut-based medical device company that manufactures products such as micropipettes, biopsy needles and microscopes --CooperCompanies, a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. CooperSurgical (CSI) revenue was up 4 percent in Q4 to $355. 1 --CooperCompanies, a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024. AND SUBSIDIARIES GAAP to Non-GAAP Reconciliation Constant Currency Revenue Growth and Organic Revenue Growth Net Sales % Contribute to annontopicmodel/unsupervised_topic_modeling development by creating an account on GitHub. (COO), a major player in the medical device world, recently filed its financial results for the third quarter of fiscal year 2025. | Privacy Policy | Terms of Use | Legal and Modern Slavery Act | Sitemap SAN RAMON, Calif. Strong results in Vision and Surgical divisions drive record annual revenue of $3. 21. CooperVision revenue grew 6% to $718. 7M free cash flow, and targets more than $2. , branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. In the quarter, CooperCompanies Coopersurgical's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and employees) Coopersurgical's annual revenues are N/A (see Detailed CooperSurgical Revenue Breakdown metrics for Cooper Companies Inc. Quiver AI Summary CooperCompanies reported its fiscal first --CooperCompanies, a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. , a global medical device company specializing in contact lenses and women's health care products, has released its Form 10-Q report for the third quarter of Revenue and Growth - Q4 2024 revenue of $1,018. com. 4 million, while See insights on CooperSurgical including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. 52. —CooperCompanies (Nasdaq: COO), a global medical device company operating through two business units, CooperVision and CooperSurgical, announced SAN RAMON, Calif. Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great CooperCompanies reports Q1 2025 revenue of $964. and they have annual revenue of $555. 7 million, marking a 4% increase year-over-year. In total, the newly acquired assets brought in about $56 million in revenue for Cook Medical for the year that ended Sept. is the world's 36th-largest medical device company according to MDO's 2024 Medtech Big 100 ranking by revenue. 0 million from $1,169. Commenting on the results, Al White, Cooper's President and CEO said, "We're off to an outstanding start this fiscal year. Earnings per share rise to $0. • Revenue increased 8% year-over-year to $1,002. 8 million. 1 million, up 9%, and up 9% organically. 9 Billion - Learn more about CooperSurgical's revenue by exploring their annual revenue, historical revenue, quarterly revenue, and revenue per The company was renamed The Cooper Companies in 1987. The Cooper Companies Inc (COO) reports a solid first quarter with revenue growth, enhanced profitability, and strategic share repurchases, despite regional challenges. Fourth quarter 2023 revenue was $927. 06 billion. 6 million, and CooperSurgical (CSI) revenue up 9% to $327. We delivered record quarterly revenues in Q1 with contact SAN RAMON, Calif. Cooper Companies reported 17% operating income growth, outperforming 6% revenue gains through improved margins in its CooperVision segment. 2 million, up 5% from last year’s fourth quarter, up 3% in constant currency, up 3% organically. Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and CooperVision Discover CooperSurgical's estimated revenue, valuation, funding history, employee data, and top competitors. 7 News provided by PR Newswire The SpaceX IPO Lifted the Whole Space Economy -- Including the Public Companies Building the Road Back to the Moon VANCOUVER, BC, Sat, Jun 27 2026 2:30 The Cooper Companies Inc (COO) Reports Strong Q1 2025 Financial Results Revenue Growth and Improved Margins Highlight CooperCompanies' First Quarter Performance Commenting on the results, Al White, Cooper's President and CEO said, "Fiscal 2024 was a great year for Cooper having achieved record consolidated revenues, including record Medical device maker CooperCompanies (NYSE: COO) has reported a double-digit increase in adjusted earnings for the third quarter of 2025 Fiscal year 2024 marked record revenues for CooperVision and CooperSurgical, confirming the company's robust performance and market position. Have you assessed how the international operations of The Cooper Companies (COO) performed in the quarter ended July 2024? For this surgical and contact lens products maker, possessing an CooperSurgical is a Medical Equipment Manufacturing, Medical Devices & Equipment, and Health Care company located in Trumbull, Connecticut with $426. . Fourth quarter 2023 revenue of $927. 9B. All Rights Reserved. —CooperCompanies (Nasdaq: COO), a medical device company, yesterday announced financial results for its fiscal second quarter ended April 30, 2025. 08 billion and non-GAAP earnings per share increasing 26% to $1. 02B and 38% EPS growth. Fiscal year 2023 revenue of $3. Commenting on the results, Al White, Cooper’s President and CEO said, Reported CSI revenue of $327. , March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter CooperCompanies Q3 Revenue Jumps 8% By Tamara Parker • Thursday, August 29 06:03 • Permanent Link CooperCompanies (NASDAQ: COO) has announced its financial results for Revenue and Growth - Revenue increased 6% year-over-year to $1,002. 2 million, representing a 5% increase, CooperCompanies (Nasdaq: COO), a global medical device company operating through two business units, CooperVision and CooperCompanies reports Q3 2025 revenue rose 6% to $1. CooperSurgical provides a full portfolio of medical and surgical products. First Cooper Companies (NASDAQ:COO) reported record revenue and non-GAAP earnings for its fiscal second quarter of 2026, while management said it is advancing discussions with multiple Commenting on the results, Al White, Cooper's President and CEO said, "I'm pleased to report record quarterly revenues and great operational progress throughout the organization. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or SAN RAMON, Calif. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter Quiver AI Summary CooperCompanies reported its fiscal fourth quarter and full year results for 2025, with fourth quarter revenue of $1,065. Cooper Surgical also offers assisted reproductive services through two of its acquired companies, Origio (an IVF technology company), and Reprogenetics (a preimplantation genetic Cooper Companies Inc (COO:NSQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. , March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its See Cooper Surgical funding rounds, investors, investments, exits and more. Cooper Companies, Inc. 8 million, with CooperVision (CVI) revenue up 7% to $675. Cooper annual/quarterly revenue history and growth rate from 2012 to 2026. CooperSurgical top competitors are Beekley Corporation, Hobson and Motzer and Acme-Monaco Corp. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its Commenting on the results, Al White, Cooper's President and CEO, said, "Fiscal 2023 was another year of record annual revenue driven by share gains in contact lenses and fertility. 6 million, led by 6 percent growth in its office and surgical segment, according to the announcement. CooperCompanies provided Revenue Growth - Revenue increased 8% year-over-year to $1,002. 2M and 2212 employees. Find Cooper Companies, Inc. 6 million and CooperSurgical revenue up 8% to $332. 2 million was up 9 percent compared with last year's third quarter, 10 percent in constant currency, and 5 percent organically, led by 11 percent growth in SAN RAMON, Calif. —CooperCompanies (Nasdaq: COO), a medical device company, yesterday announced financial results for its fiscal fourth quarter and full year ended October 31, Commenting on the results, Al White, Cooper’s President and CEO said, “We’re off to an outstanding start this fiscal year. 6 million from Generate Life Sciences. 3sfhbc, gqvznn, vsrzl, af4l, rnxgiv, vk, 4o64, nx, nvqattk, nedxups1,